Competitor Analysis: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists is a new market research publication announced by Reportstack. The Competitive Intelligence Report Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists as of August 2014 provides a competitor analysis in the development pipeline of novel GLP-1 analogs and GLP-1 receptor agonists and co-agonists for treatment of diabetes and obesity.
In the year 2013, the marketed daily and weekly GLP-1 agonists achieved combined sales of US$ 3,231 mln representing 6.3% of the total diabetes care market. The leading GLP-1 analog Victoza held 69% of the GLP-1 market and is further expanding its predominance in the first half of 2014 with a 72% share of the GLP-1 market which grew to 6.9% of the total diabetes care market.
The increasingly attractive GLP-1 market provides an opportunity of application of new technologies to prolong the half-life of GLP-1 analogs as well as finding co-agonists of GLP-1 receptor with additional receptors, such as insulin, glucagon, GIP, gastrin or GLP-1. In addition, expansion of indications for GLP-1 analogs will contribute to further expand the GLP-1 market.
The report provides a compilation of current active projects in research and development of novel GLP-1 analogs and GLP-1 receptor agonists as well as co-agonists. Competitor projects are listed in a tabular format providing information on:
Drug Codes,Target /Mechanism of Action,Class of Compound,Company, Product Category,Indication,R&D Stage and additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Companies mentioned
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
Companies mentioned in the report
Addex Therapeutics
Aegis Therapeutics
Alteogen
Amunix
Arisaph Pharmaceuticals
Arisgen
AstraZeneca (MedImmune)
Boehringer Ingelheim
Camurus
ConjuChem
Dong-A Pharmaceutical (Dong-A Socio Holding)
Eli Lilly
Flamel Technologies
Foresee Pharmaceuticals
Genexine
GlaxoSmithKline
Hanmi Pharmaceuticals
Heptares Therapeutics
Il-Dong Pharma
ImmuPharma
Intarcia Therapeutics
Jiangsu HengRui Medicine Co
LG Life Science
MannKind
Midasol Therapeutics
MultiMedica
Novo Nordisk
OJSC PharmSynthez
OPKO Health
Oramed Pharmaceuticals
PegBio
Peptron
PharmaIn
PhaseBio
Poxel
Proxima Concepts
Receptos
Roche
Sanofi
Serometrix
Spitfire Pharma
TransTech Pharma
Uni-Bio Science
Xenetic Biosciences
Yuhan
Zealand Pharma
In the year 2013, the marketed daily and weekly GLP-1 agonists achieved combined sales of US$ 3,231 mln representing 6.3% of the total diabetes care market. The leading GLP-1 analog Victoza held 69% of the GLP-1 market and is further expanding its predominance in the first half of 2014 with a 72% share of the GLP-1 market which grew to 6.9% of the total diabetes care market.
The increasingly attractive GLP-1 market provides an opportunity of application of new technologies to prolong the half-life of GLP-1 analogs as well as finding co-agonists of GLP-1 receptor with additional receptors, such as insulin, glucagon, GIP, gastrin or GLP-1. In addition, expansion of indications for GLP-1 analogs will contribute to further expand the GLP-1 market.
The report provides a compilation of current active projects in research and development of novel GLP-1 analogs and GLP-1 receptor agonists as well as co-agonists. Competitor projects are listed in a tabular format providing information on:
Drug Codes,Target /Mechanism of Action,Class of Compound,Company, Product Category,Indication,R&D Stage and additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Companies mentioned
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
Companies mentioned in the report
Addex Therapeutics
Aegis Therapeutics
Alteogen
Amunix
Arisaph Pharmaceuticals
Arisgen
AstraZeneca (MedImmune)
Boehringer Ingelheim
Camurus
ConjuChem
Dong-A Pharmaceutical (Dong-A Socio Holding)
Eli Lilly
Flamel Technologies
Foresee Pharmaceuticals
Genexine
GlaxoSmithKline
Hanmi Pharmaceuticals
Heptares Therapeutics
Il-Dong Pharma
ImmuPharma
Intarcia Therapeutics
Jiangsu HengRui Medicine Co
LG Life Science
MannKind
Midasol Therapeutics
MultiMedica
Novo Nordisk
OJSC PharmSynthez
OPKO Health
Oramed Pharmaceuticals
PegBio
Peptron
PharmaIn
PhaseBio
Poxel
Proxima Concepts
Receptos
Roche
Sanofi
Serometrix
Spitfire Pharma
TransTech Pharma
Uni-Bio Science
Xenetic Biosciences
Yuhan
Zealand Pharma
To view the table of contents and know more details please visit Competitor Analysis: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists.
No comments:
Post a Comment